AIM Vaccine's 20-Valent Pneumococcal Conjugate Vaccine Receives Clinical Approval, Upgraded Iterative Major Product Expected to Seize Domestic Opportunities

AIM Vaccine's 20-Valent Pneumococcal Conjugate Vaccine Receives Clinical Approval, Upgraded Iterative Major Product Expected to Seize Domestic Opportunities

HONG KONG, Jan. 20, 2026 /PRNewswire/ -- AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on January 19 that it has developed an optimized upgraded version of its iterative 20-valent pneumococcal conjugate vaccine, which has...

Full Truck Alliance Co. Ltd. Announces Long-Term Shareholder Return Plan

Full Truck Alliance Co. Ltd. Announces Long-Term Shareholder Return Plan

GUIYANG, China, Jan. 19, 2026 /PRNewswire/ -- Full Truck Alliance Co. Ltd. ("FTA" or the "Company") (NYSE: YMM), a leading digital freight platform, today announced that, in order to carry out its long-term commitment to returning value to...

The AKG and Ca-AKG of Xin Tianhe have passed the US Self-GRAS certification

The AKG and Ca-AKG of Xin Tianhe have passed the US Self-GRAS certification

SHENZHEN, China, Jan. 16, 2026 /PRNewswire/ -- On January 7, 2026, the AKG and Ca-AKG of Xin Tianhe Biotechnology successfully completed the Self-GRAS scientific evaluation in accordance with the US FDA GRAS standards and were approved and became...

Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD

Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD

SHANGHAI, Jan. 8, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and...

Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD

Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD

SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and...

Keywords for AIIB's first decade: multilateral cooperation, mutual connectivity, extensive consultation, and joint contribution

Keywords for AIIB's first decade: multilateral cooperation, mutual connectivity, extensive consultation, and joint contribution

BEIJING, Dec. 25, 2025 /PRNewswire/ -- A news report from China.org.cn on AIIB's first decade: Keywords for AIIB's first decade: multilateral cooperation, mutual connectivity, extensive consultation, and joint contribution In a primary school...

China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval

China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval

TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant treatment of patients with stage IIB-III resectable microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR)...

Elong Power Holding Limited Announces Effective Date of Reverse Stock Split

Elong Power Holding Limited Announces Effective Date of Reverse Stock Split

BEIJING, Dec. 23, 2025 /PRNewswire/ -- Elong Power Holding Limited ("Elong Power" or the "Company") (Nasdaq: ELPW), a provider of high power battery technologies for commercial and specialty alternative energy vehicles and energy storage systems,...

Three More Coway Airmega Air Purifiers Approved by Sensitive Choice for Australians with Allergies and Asthma

Three More Coway Airmega Air Purifiers Approved by Sensitive Choice for Australians with Allergies and Asthma

- Three additional Coway Airmega models have been recognised by the National Asthma Council Australia for their potential to benefit those living with asthma and allergies. SYDNEY, Dec. 23, 2025 /PRNewswire/ -- For the millions of Australians living...

Guardant Health Japan receives regulatory approval of Guardant360® CDx liquid biopsy as companion diagnostic for imlunestrant in metastatic or recurrent breast cancer previously treated with endocrine therapy

Guardant Health Japan receives regulatory approval of Guardant360® CDx liquid biopsy as companion diagnostic for imlunestrant in metastatic or recurrent breast cancer previously treated with endocrine therapy

Guardant360® CDx is the first companion diagnostic to be approved in Japan to identify ESR1 mutations in patients with hormone receptor-positive, HER2-negative breast cancer for treatment with imlunestrant TOKYO, Dec. 22, 2025 /PRNewswire/ --...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 15
  • menu
    menu